Moxidectin (ProHeart)

Moxidectin is a macrocyclic lactone anthelmintic medication that provides extended-duration heartworm prevention in dogs through innovative sustained-release injectable formulations. Marketed under the ProHeart brand name, moxidectin represents a significant advancement in heartworm prevention by offering protection lasting either six months (ProHeart 6) or twelve months (ProHeart 12) from a single injection administered by a veterinarian. This extended protection eliminates the challenges associated with monthly dosing, ensuring continuous heartworm prevention without relying on owner compliance for regular administration. ProHeart products have become valuable options for dogs and owners seeking convenient, long-lasting protection against the serious threat of heartworm disease.

The mechanism of action of moxidectin parallels that of other macrocyclic lactones, targeting glutamate-gated chloride channels in parasite nerve and muscle cells. When moxidectin binds to these channels, it causes increased permeability to chloride ions, resulting in hyperpolarization, paralysis, and death of the parasite. This mechanism effectively eliminates the larval stages of heartworms (Dirofilaria immitis) that mosquitoes transmit to dogs, preventing these larvae from developing into adult worms that cause cardiovascular and pulmonary damage. The sustained-release technology of ProHeart products releases moxidectin gradually over months, maintaining effective drug levels in the bloodstream to provide continuous protection throughout the extended dosing interval.

ProHeart injectable products utilize sophisticated microsphere technology to achieve their extended-release properties. The moxidectin is encapsulated within lipid microspheres that slowly release the drug over time following subcutaneous injection. ProHeart 6 provides approximately six months of heartworm prevention, while ProHeart 12 extends protection to approximately twelve months. Both products also provide treatment and control of hookworm infections at the time of injection. The injection is administered by veterinary professionals during a clinic visit, after which the dog is protected without any additional intervention required until the next scheduled injection.

The safety profile of ProHeart injectable products has been established through extensive clinical trials and post-market surveillance. Following a voluntary market withdrawal in 2004 to investigate adverse event reports and implement enhanced safety protocols, ProHeart 6 returned to the market in 2008 with updated labeling and recommendations. ProHeart 12 was subsequently approved in 2019. Current protocols include pre-injection health assessment and specific precautions for patient selection. As with all macrocyclic lactones, dogs with the MDR1 gene mutation may have increased sensitivity to moxidectin, and appropriate evaluation is recommended before treatment. When used according to current guidelines with proper patient selection, ProHeart products provide effective heartworm protection with an acceptable safety profile for most dogs.

The primary indication for injectable moxidectin is the prevention of heartworm disease caused by Dirofilaria immitis in dogs. Heartworm disease remains a significant health threat to dogs throughout many regions of the world, transmitted through the bites of infected mosquitoes carrying heartworm larvae. Without prevention, these microscopic larvae develop over approximately six months into adult worms that can grow up to twelve inches in length and reside in the heart, pulmonary arteries, and lungs. Adult heartworms cause progressive cardiovascular damage, respiratory compromise, and can be fatal if left untreated. ProHeart injectable moxidectin provides long-duration protection by maintaining effective drug concentrations that eliminate heartworm larvae before they can mature into damaging adult worms.

The extended-duration protection offered by ProHeart products addresses one of the primary challenges in heartworm prevention, which is owner compliance with monthly dosing schedules. Studies have shown that many dog owners struggle to maintain consistent monthly administration of oral heartworm preventatives, whether due to forgetfulness, busy schedules, difficulty medicating their pets, or other factors. Each missed dose creates a window of vulnerability during which transmitted heartworm larvae can progress beyond the stage where preventatives are effective. By providing six or twelve months of continuous protection from a single injection, ProHeart ensures that dogs remain protected regardless of the challenges that can interfere with monthly dosing.

In addition to heartworm prevention, ProHeart products provide treatment and control of hookworm infections at the time of administration. Hookworms (Ancylostoma caninum and Uncinaria stenocephala) are common intestinal parasites that can cause anemia, diarrhea, and other health problems, particularly in puppies and dogs with heavy infections. The moxidectin released from ProHeart injections eliminates existing hookworm infections at the time of injection. However, unlike the sustained heartworm prevention, the hookworm activity is primarily at the time of injection rather than throughout the extended dosing interval, so dogs with ongoing hookworm exposure may require additional intestinal parasite control.

ProHeart products are particularly valuable for certain populations of dogs and ownership situations. Dogs that are difficult to medicate orally benefit from the injectable route of administration, as the single injection given by the veterinarian eliminates the need for the owner to give monthly pills or chewables. Dogs whose owners travel frequently or have unpredictable schedules are protected without depending on regular at-home dosing. Multiple-pet households may find the extended-duration option simplifies their preventive care routine. Dogs that have experienced gaps in monthly prevention due to compliance issues gain reliable protection with ProHeart. Working dogs, service dogs, and dogs in professional settings may benefit from the predictable protection schedule that aligns with regular veterinary visits.

Veterinarians select ProHeart products for dogs based on individual patient evaluation and owner considerations. The injectable route ensures that the full dose is delivered properly, eliminating concerns about incomplete consumption of oral products. The veterinary administration also provides regular touchpoints for health assessment, as dogs must visit the clinic for each injection. The twelve-month formulation aligns conveniently with annual wellness examinations. For dogs in geographic areas with year-round heartworm transmission, the extended protection ensures no seasonal gaps in coverage. When choosing between ProHeart 6 and ProHeart 12, factors include the dog's individual health status, owner preferences regarding visit frequency, and regional heartworm risk patterns.

Moxidectin in ProHeart formulations is administered exclusively by veterinary professionals as a subcutaneous injection, ensuring proper dosing and immediate supervision for any adverse reactions. The dosing protocol is weight-based, with each product formulated to deliver the appropriate amount of moxidectin based on the dog's body weight at the time of injection. ProHeart 6 provides approximately six months of heartworm protection, while ProHeart 12 extends this to approximately twelve months. Your veterinarian will determine the appropriate product and dosing based on your dog's current health status, weight, and individual circumstances. The sustained-release microsphere technology maintains effective moxidectin concentrations throughout the protection period.

Before receiving a ProHeart injection, dogs must undergo evaluation to confirm they are appropriate candidates for the medication. This includes testing for existing heartworm infection, as administering preventatives to dogs already infected with adult heartworms can cause adverse reactions and will not eliminate the existing infection. A general health assessment ensures that the dog does not have conditions that might contraindicate moxidectin use. The dog should be weighed accurately to ensure proper dosing. Dogs must be at least six months of age and in good health to receive ProHeart 12, while ProHeart 6 can be administered to dogs at least six months of age as well. Some veterinarians may recommend additional evaluation for dogs with certain risk factors.

The injection is administered subcutaneously, typically between the shoulder blades or in another appropriate location determined by the veterinarian. The microsphere suspension requires proper preparation according to the manufacturer's instructions to ensure correct drug delivery. Following injection, the veterinarian or technician will observe the dog briefly for any immediate reactions before the pet is released to go home. The injection site may show mild, temporary reactions such as slight swelling or sensitivity in some dogs, which typically resolve without intervention. Owners should be informed about what to watch for at home following the injection.

The scheduling of ProHeart injections is designed to maintain continuous heartworm protection without gaps in coverage. For ProHeart 6, dogs should return for their next injection approximately six months after the previous one. For ProHeart 12, the annual injection is typically coordinated with the dog's yearly wellness examination, providing convenient timing for comprehensive preventive care. It is important to adhere to the recommended schedule, as delays between injections could create periods of vulnerability to heartworm infection. If a scheduled injection is delayed, consult with your veterinarian about whether heartworm testing is needed before administering the next dose.

Dogs transitioning to ProHeart from monthly heartworm preventatives can typically receive their first injection at the time of their next monthly dose, ensuring continuous protection without overlap concerns. Dogs that have experienced gaps in heartworm prevention should be tested before starting ProHeart to ensure they have not become infected. Puppies starting heartworm prevention are typically maintained on monthly preventatives until they reach six months of age and can receive their first ProHeart injection. The timing of the injection relative to mosquito season is less critical with ProHeart than with monthly preventatives since the extended protection eliminates seasonal compliance concerns.

Annual heartworm testing remains recommended for dogs receiving ProHeart, despite the extended protection period. Testing confirms that the prevention has been effective and provides early detection in the unlikely event of treatment failure. Many veterinary practices incorporate heartworm testing into the visit when dogs receive their ProHeart 12 injection, combining the annual test with the annual preventive injection. For dogs on ProHeart 6, testing schedules should be discussed with your veterinarian based on regional recommendations and individual circumstances.

Injectable moxidectin in ProHeart formulations has demonstrated acceptable safety when used according to current guidelines with appropriate patient selection. Clinical trials and post-market surveillance have provided extensive data on the side effect profile of these products. The majority of dogs receiving ProHeart injections experience no significant adverse effects. However, as with any medication, some dogs may experience reactions ranging from mild and transient to more serious, and owner awareness of potential effects enables prompt recognition and response when needed.

The most commonly observed adverse effects following ProHeart injection are mild and typically resolve without specific treatment. Injection site reactions, including localized swelling, pain, or inflammation where the injection was administered, occur in some dogs and usually resolve within a few days. Lethargy or decreased activity may be noted by some owners in the day or two following injection. Gastrointestinal effects including vomiting, diarrhea, or decreased appetite are occasionally reported and typically self-limiting. These common reactions, when they occur, generally do not require veterinary intervention but should be monitored to ensure they resolve appropriately.

Less common side effects may include more pronounced or persistent lethargy, fever, or allergic-type reactions. Some dogs may show signs of discomfort beyond mild injection site sensitivity. Skin reactions at sites other than the injection site, including itching or hives, have been reported and may indicate a systemic response to the medication. Weight loss has been noted in some dogs during clinical trials. Neurological effects including incoordination, tremors, or seizures are uncommon but have been reported, particularly in dogs with potential drug sensitivities. Any symptoms that are concerning, severe, or persistent should prompt veterinary consultation.

Serious adverse reactions to ProHeart products are rare but have been reported and contributed to the enhanced safety protocols now in place. The original ProHeart 6 product was voluntarily withdrawn from the market in 2004 following reports of severe adverse reactions including death in some treated dogs. After extensive review and implementation of updated guidelines for patient selection and post-treatment monitoring, the reformulated product returned to the market in 2008 with improved safety labeling. Current recommendations emphasize the importance of treating only healthy dogs, performing pre-treatment health assessments, and being prepared to manage adverse events if they occur. Signs of severe reactions requiring immediate veterinary attention include difficulty breathing, collapse, severe facial swelling, pale gums, or any concerning changes in the hours or days following injection.

Dogs with the MDR1 gene mutation may have increased sensitivity to moxidectin, as with other macrocyclic lactones. The mutation affects the blood-brain barrier's ability to exclude these drugs from the central nervous system, potentially resulting in neurological toxicity. Breeds commonly affected include Collies, Australian Shepherds, Shetland Sheepdogs, Border Collies, and related herding breeds. While the sustained-release formulation of ProHeart delivers moxidectin gradually rather than as a bolus dose, dogs with MDR1 sensitivity may still be at increased risk for adverse effects. Genetic testing is available and recommended for at-risk breeds before ProHeart administration. Dogs known to carry the MDR1 mutation should be carefully evaluated to determine if alternative heartworm prevention might be more appropriate, and if ProHeart is used, close monitoring is essential.

ProHeart injectable moxidectin is contraindicated in dogs with known hypersensitivity to moxidectin or other macrocyclic lactone compounds. Dogs that have previously experienced allergic reactions or significant adverse effects following administration of any macrocyclic lactone medication, including ivermectin, milbemycin, or selamectin, may be at increased risk for reactions to moxidectin and should not receive ProHeart without careful veterinary evaluation. A thorough medication history that includes any previous adverse drug reactions helps ensure safe treatment decisions and should be discussed with your veterinarian before your dog receives ProHeart.

Dogs with existing heartworm infection should not receive ProHeart or any heartworm preventative until their infection has been appropriately addressed. Administering preventative medications to dogs infected with adult heartworms can cause serious reactions, particularly when circulating microfilariae are present in the bloodstream. The rapid killing of microfilariae can trigger shock-like reactions and inflammatory responses. Therefore, all dogs must be tested for heartworm infection before receiving their first ProHeart injection, and annual testing is recommended to ensure continued heartworm-negative status. Dogs that test positive require appropriate adulticide treatment under veterinary supervision before preventive therapy can be initiated.

ProHeart products have specific age and health requirements that must be met before administration. Dogs must be at least six months of age to receive either ProHeart 6 or ProHeart 12. Younger puppies should receive monthly heartworm preventatives until they reach the appropriate age for injectable prevention. Dogs must be in good health at the time of injection, as the product label specifies administration to healthy dogs only. Dogs that are sick, debilitated, underweight, have recently undergone surgery, or are experiencing concurrent illness should have their ProHeart injection delayed until they have recovered. Your veterinarian will assess your dog's overall health status before determining if ProHeart is appropriate.

Breed-specific sensitivities related to the MDR1 gene mutation represent a significant consideration for ProHeart use. While the sustained-release formulation delivers moxidectin gradually, dogs carrying the MDR1 mutation may still experience adverse effects due to their reduced ability to clear the drug from the central nervous system. Breeds with high prevalence of the MDR1 mutation include Collies, Australian Shepherds, Shetland Sheepdogs, Old English Sheepdogs, Border Collies, German Shepherds, and mixed breeds with herding heritage. For these dogs, genetic testing is strongly recommended before ProHeart administration. Dogs confirmed to be homozygous for the mutation (carrying two copies) are at highest risk and may be better served by alternative heartworm prevention strategies after consultation with their veterinarian.

Additional precautions apply to specific populations. The safety of ProHeart in breeding dogs has not been evaluated, so dogs intended for breeding should have their heartworm prevention options discussed with their veterinarian. Pregnant and lactating dogs should not receive ProHeart, as safety has not been established in these populations. Dogs with significant liver or kidney disease may have altered drug metabolism and require veterinary evaluation before treatment. Dogs receiving other medications should have potential interactions assessed. Complete disclosure of your dog's health history and current medications to your veterinarian ensures that ProHeart is an appropriate choice for your individual pet.

Understanding potential drug interactions is important for safe use of injectable moxidectin, as concurrent medications can affect how the drug is processed in the body or increase the risk of adverse effects. Moxidectin, like other macrocyclic lactones, is a substrate for P-glycoprotein, a transport protein involved in drug elimination and blood-brain barrier function. Medications that inhibit P-glycoprotein can increase moxidectin concentrations, potentially leading to toxicity, especially in dogs with compromised P-glycoprotein function due to the MDR1 mutation. Before your dog receives a ProHeart injection, provide your veterinarian with a complete list of all medications, supplements, and over-the-counter products your dog is receiving.

Several drug classes have been identified as potential interactors with macrocyclic lactones. Spinosad, the active ingredient in some oral flea control products, has been associated with elevated levels of ivermectin when used concurrently, and similar concerns may apply to moxidectin. While many dogs receive both types of products without apparent problems, the sustained-release nature of ProHeart means that any interaction would persist throughout the extended dosing period. Azole antifungal medications including ketoconazole can inhibit P-glycoprotein and potentially increase moxidectin levels in the body. Cyclosporine, used for immune-mediated conditions, also affects drug transport mechanisms. If your dog requires these medications, your veterinarian will assess the risks and benefits of concurrent use.

The extended-release nature of ProHeart creates unique considerations for drug interaction management compared to monthly preventatives. Because moxidectin continues to be released from the microspheres for months after injection, any interacting drug started during this period could theoretically affect moxidectin levels. Conversely, the interaction potential must be considered for the full duration of the ProHeart protection period when planning new medication introductions. If your dog requires new medications during the months following a ProHeart injection, inform the prescribing veterinarian that your dog has received this long-acting preventative so interactions can be evaluated.

Dietary and supplement interactions with moxidectin are generally not well characterized, though the sustained-release injectable formulation bypasses the gastrointestinal tract, making food interactions less relevant than they might be for oral medications. Most common canine supplements including joint supplements, fish oils, and probiotics are not known to significantly interact with moxidectin. However, some herbal supplements may have unpredictable effects on drug metabolism or P-glycoprotein function. Complete disclosure of all supplements to your veterinarian allows for comprehensive interaction assessment.

Communication with your veterinary team is essential for managing potential drug interactions throughout the ProHeart protection period. Before any new medication is prescribed, whether by your regular veterinarian, an emergency clinic, or a specialist, ensure that the prescribing veterinarian knows your dog is receiving long-acting moxidectin. Carry documentation of your dog's ProHeart injection date and product for reference. Watch for any changes in your dog's behavior or health following introduction of new medications, as this could indicate an interaction. Regular veterinary visits provide opportunities to review your dog's complete medication profile and adjust treatment as needed.

The most important precautionary consideration for ProHeart injectable moxidectin involves appropriate patient selection and health assessment before administration. Current product labeling emphasizes administration to healthy dogs only, reflecting lessons learned from post-market surveillance following the original product introduction. Before receiving a ProHeart injection, dogs should undergo examination by a veterinarian to assess overall health status and identify any conditions that might increase risk of adverse reactions. This health screening is not merely procedural but represents an important safety measure that contributes to the favorable benefit-risk profile seen when the product is used according to current guidelines.

Breed-specific sensitivities related to the MDR1 gene mutation require careful consideration before ProHeart administration. Dogs carrying this mutation have impaired ability to exclude moxidectin and other macrocyclic lactones from the central nervous system, potentially resulting in neurological toxicity. Collies have the highest prevalence of this mutation, but Australian Shepherds, Shetland Sheepdogs, Border Collies, Old English Sheepdogs, German Shepherds, and related breeds also have significant affected populations. Mixed breed dogs with any herding breed heritage should be considered potentially at risk. Genetic testing is readily available through veterinary clinics and commercial laboratories. For dogs known to carry the MDR1 mutation, particularly those homozygous for the affected gene, your veterinarian may recommend alternative heartworm prevention approaches.

Post-injection observation and monitoring contribute to safe ProHeart use. Dogs should be observed for a brief period after injection before leaving the veterinary clinic to ensure no immediate adverse reactions occur. Owners should monitor their dogs at home following injection, watching for signs of injection site reactions, lethargy, gastrointestinal upset, or any unusual symptoms. The first 24 to 48 hours following injection are the most likely period for reactions to become apparent, though some effects may develop later. Any concerning symptoms should be reported to your veterinarian promptly. Because ProHeart releases medication over an extended period, adverse effects related to the drug can potentially occur at any time during the protection period.

The extended-duration nature of ProHeart creates considerations distinct from monthly preventatives. Once administered, the medication cannot be removed if a problem develops, unlike oral medications that are eventually eliminated from the body. While supportive care can be provided for adverse reactions, the ongoing release of moxidectin from the microspheres cannot be stopped. This underscores the importance of careful patient selection before injection. Dog owners should understand this characteristic of the product and be comfortable with the extended-release nature before electing ProHeart over monthly alternatives.

Special populations require additional consideration when evaluating ProHeart suitability. Dogs must be at least six months of age before receiving ProHeart, with younger puppies maintained on monthly preventatives until they reach appropriate age. Senior dogs should have their overall health status assessed, as age-related organ function changes may affect drug handling. Dogs with liver or kidney disease require careful evaluation. Dogs that are underweight, recently ill, or recovering from surgery should have their injection delayed until they have returned to good health. Working dogs and performance animals should have their activity and stress levels considered. The safety of ProHeart in breeding, pregnant, or lactating dogs has not been established, and these animals should receive alternative heartworm prevention.

ProHeart injectable moxidectin products require specific storage conditions to maintain their stability and effectiveness. These products are stored and handled by veterinary clinics rather than dispensed for home use, ensuring proper storage conditions are maintained. The microsphere suspension that provides the sustained-release properties of ProHeart is sensitive to temperature and handling, making appropriate storage essential. Veterinary practices follow manufacturer guidelines for storing these products, typically requiring refrigeration before reconstitution and use within specified timeframes after preparation.

The storage requirements for ProHeart products are designed to preserve the integrity of the microsphere formulation. Extreme temperatures, whether heat or cold, can affect the microspheres and potentially alter drug release characteristics. Exposure to light can degrade the medication over time. Because these products are maintained and administered within veterinary facilities, pet owners do not need to manage storage themselves, but can be confident that proper handling protocols are followed by veterinary professionals. Veterinary clinics monitor expiration dates and rotate stock to ensure that patients receive medication that meets all quality specifications.

Because ProHeart is administered exclusively in veterinary settings, the handling considerations differ from those of at-home heartworm preventatives. Pet owners do not need to worry about secure storage away from pets and children, proper disposal of unused medication, or other concerns associated with home medication storage. The injection is prepared and administered by trained veterinary staff following established protocols. This professional handling eliminates many of the storage and administration errors that can occur with medications kept and given at home.

For pet owners, the primary handling consideration is ensuring their dog receives ProHeart on the recommended schedule by maintaining regular veterinary appointments. Setting reminders for upcoming injection dates helps ensure continuous protection. Keeping records of when ProHeart was administered, including the specific product (ProHeart 6 or ProHeart 12) and the date, provides useful reference information for you and any veterinary professional who may see your dog. Some veterinary clinics offer reminder systems that notify owners when their dog's next ProHeart injection is due. Because the extended-duration formulation requires fewer doses, each injection date becomes more critical to remember than monthly dosing schedules.

While ProHeart injectable moxidectin can be appropriate for dogs of many breeds, certain breed-specific factors significantly influence suitability for this extended-release formulation. The most important breed consideration involves the MDR1 (ABCB1) gene mutation, which affects drug metabolism and can cause sensitivity to moxidectin and related macrocyclic lactones. Because ProHeart delivers medication over an extended period that cannot be reversed once injected, careful evaluation of genetic risk factors is particularly important before administration.

Breeds with documented high prevalence of the MDR1 mutation require special consideration when ProHeart is being evaluated as a heartworm prevention option. Collies carry this mutation at the highest rate, with approximately 70% of individuals affected. Australian Shepherds have a prevalence of approximately 50%, making this breed particularly important to evaluate. Shetland Sheepdogs, Old English Sheepdogs, Border Collies, English Shepherds, and German Shepherds also have notable mutation rates. Long-haired Whippets and Silken Windhounds carry the mutation as well. Mixed breed dogs with any herding breed heritage, even if not obviously apparent from the dog's appearance, should be considered potentially at risk. Genetic testing provides definitive information about MDR1 status and is strongly recommended for dogs of these breeds before ProHeart administration.

For dogs confirmed to carry the MDR1 mutation, particularly those homozygous for the affected gene, veterinarians often recommend alternative heartworm prevention strategies. The extended-release nature of ProHeart means that if an adverse reaction develops, the drug will continue to be released for months, unlike single-dose monthly preventatives that are eventually eliminated from the body. This characteristic makes alternative monthly preventatives, which clear from the system more quickly if problems arise, potentially safer choices for MDR1-affected dogs. However, the decision should be individualized based on the specific mutation status (heterozygous versus homozygous), the individual dog's sensitivity, and consultation with your veterinarian.

Size considerations are relevant for all breeds receiving ProHeart. The injectable formulation is dosed based on body weight, and dogs must meet minimum weight requirements specified on the product label. Giant breeds may require larger injection volumes, while toy breeds must meet minimum weight thresholds. Accurate weight measurement before each injection ensures appropriate dosing. Growing dogs may transition between weight categories during the extended dosing period, so weight should be reassessed at each injection appointment. Age requirements apply regardless of breed, with dogs needing to be at least six months old before receiving either ProHeart formulation. Senior dogs of any breed should have their overall health status assessed before administration, with particular attention to liver and kidney function that may decline with age.

Several alternative heartworm preventatives offer options for dogs that may not be suitable candidates for ProHeart or whose owners prefer different administration methods. Monthly oral macrocyclic lactones including ivermectin (Heartgard) and milbemycin oxime (Interceptor) provide effective heartworm prevention with more frequent dosing that allows medication to clear the system more quickly if adverse effects develop. These monthly alternatives may be preferred for dogs with the MDR1 mutation or other risk factors for macrocyclic lactone sensitivity. Selamectin (Revolution) offers topical monthly heartworm prevention along with flea control. Each alternative has specific advantages depending on individual patient factors, owner preferences, and lifestyle considerations.

Within the extended-release category, ProHeart 6 and ProHeart 12 offer different duration options for dogs receiving injectable moxidectin. ProHeart 6 provides approximately six months of protection, requiring two injections per year, while ProHeart 12 extends protection to approximately twelve months with annual dosing. The choice between these options may depend on owner preferences regarding visit frequency, veterinarian recommendations based on regional heartworm transmission patterns, and individual patient factors. Dogs new to ProHeart might start with ProHeart 6 to evaluate tolerance before transitioning to the longer-duration product, though this is not required.

Complementary approaches support comprehensive parasite control alongside heartworm prevention with ProHeart. Because ProHeart provides treatment for hookworms only at the time of injection rather than throughout the protection period, dogs with ongoing intestinal parasite exposure may need additional deworming during the interval between injections. Flea and tick prevention is not provided by ProHeart and must be addressed with separate products if needed. Regular fecal examinations help detect intestinal parasites that require treatment. Environmental management including mosquito control around the home reduces heartworm transmission risk, though this should never substitute for preventative medication. Always consult with your veterinarian before making changes to your dog's heartworm prevention protocol, as maintaining continuous protection is essential for preventing this serious and potentially fatal disease.